Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294549596> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4294549596 endingPage "1046" @default.
- W4294549596 startingPage "1046" @default.
- W4294549596 abstract "<h3>Objective.</h3> —To evaluate the efficacy of a 10-mg dose of midodrine 3 times per day in improving blood pressure (BP) and ameliorating symptoms of orthostatic hypotension in patients with neurogenic orthostatic hypotension. Midodrine hydrochloride, an α=agonist, could improve orthostatic BP by increasing vasomotor and venomotor tone. <h3>Design/Methods.</h3> —A total of 171 patients with orthostatic hypotension participated in a multicenter, randomized, placebo-controlled study. They were randomized to a 10-mg dose of midodrine or placebo 3 times per day in a 6-week study, comprising single-blind run-in (at week 1) and washout at weeks 5 and 6, with an intervening double-blind period (weeks 2 to 4). <h3>Setting.</h3> —Twenty-five centers, with most patients evaluated in referral centers. <h3>Main Outcome Measures.</h3> —The primary end points were improvement in standing systolic BP, symptoms of lightheadedness, and a global symptom relief score (by the investigator and patient separately). <h3>Results.</h3> —Nine patients were not evaluable because of noncompliance or taking concomitant vasoactive medications (3 in the midodrine group, 6 in the placebo group). In the evaluable patients, midodrine resulted in improvements in standing systolic BP at all time points (<i>P</i><.001 at visits 2,3,4, and 5), in reported symptoms by the end of the second week of treatment (<i>P</i>=.001), and in the global symptom relief score rated by both the patient (<i>P</i>=.03) and the investigator (<i>P</i><.001). There was no effect by center, severity of orthostatic hypotension, use of fludrocortisone or compression garments, or diagnosis. The main adverse effects were those of pilomotor reactions, urinary retention, and supine hypertension. <h3>Conclusions.</h3> —Midodrine is efficacious and safe in the treatment of neurogenic orthostatic hypotension." @default.
- W4294549596 created "2022-09-04" @default.
- W4294549596 creator A5047373167 @default.
- W4294549596 date "1997-04-02" @default.
- W4294549596 modified "2023-10-17" @default.
- W4294549596 title "Efficacy of Midodrine vs Placebo in Neurogenic Orthostatic Hypotension" @default.
- W4294549596 doi "https://doi.org/10.1001/jama.1997.03540370036033" @default.
- W4294549596 hasPublicationYear "1997" @default.
- W4294549596 type Work @default.
- W4294549596 citedByCount "307" @default.
- W4294549596 countsByYear W42945495962012 @default.
- W4294549596 countsByYear W42945495962013 @default.
- W4294549596 countsByYear W42945495962014 @default.
- W4294549596 countsByYear W42945495962015 @default.
- W4294549596 countsByYear W42945495962016 @default.
- W4294549596 countsByYear W42945495962017 @default.
- W4294549596 countsByYear W42945495962018 @default.
- W4294549596 countsByYear W42945495962019 @default.
- W4294549596 countsByYear W42945495962020 @default.
- W4294549596 countsByYear W42945495962021 @default.
- W4294549596 countsByYear W42945495962022 @default.
- W4294549596 countsByYear W42945495962023 @default.
- W4294549596 crossrefType "journal-article" @default.
- W4294549596 hasAuthorship W4294549596A5047373167 @default.
- W4294549596 hasConcept C126322002 @default.
- W4294549596 hasConcept C142724271 @default.
- W4294549596 hasConcept C197934379 @default.
- W4294549596 hasConcept C204787440 @default.
- W4294549596 hasConcept C27081682 @default.
- W4294549596 hasConcept C2777706214 @default.
- W4294549596 hasConcept C2778375690 @default.
- W4294549596 hasConcept C2780081974 @default.
- W4294549596 hasConcept C2781177144 @default.
- W4294549596 hasConcept C42219234 @default.
- W4294549596 hasConcept C71924100 @default.
- W4294549596 hasConcept C73787029 @default.
- W4294549596 hasConcept C84393581 @default.
- W4294549596 hasConceptScore W4294549596C126322002 @default.
- W4294549596 hasConceptScore W4294549596C142724271 @default.
- W4294549596 hasConceptScore W4294549596C197934379 @default.
- W4294549596 hasConceptScore W4294549596C204787440 @default.
- W4294549596 hasConceptScore W4294549596C27081682 @default.
- W4294549596 hasConceptScore W4294549596C2777706214 @default.
- W4294549596 hasConceptScore W4294549596C2778375690 @default.
- W4294549596 hasConceptScore W4294549596C2780081974 @default.
- W4294549596 hasConceptScore W4294549596C2781177144 @default.
- W4294549596 hasConceptScore W4294549596C42219234 @default.
- W4294549596 hasConceptScore W4294549596C71924100 @default.
- W4294549596 hasConceptScore W4294549596C73787029 @default.
- W4294549596 hasConceptScore W4294549596C84393581 @default.
- W4294549596 hasIssue "13" @default.
- W4294549596 hasLocation W42945495961 @default.
- W4294549596 hasOpenAccess W4294549596 @default.
- W4294549596 hasPrimaryLocation W42945495961 @default.
- W4294549596 hasRelatedWork W1986430037 @default.
- W4294549596 hasRelatedWork W1997633764 @default.
- W4294549596 hasRelatedWork W2032663810 @default.
- W4294549596 hasRelatedWork W2105259937 @default.
- W4294549596 hasRelatedWork W2406646079 @default.
- W4294549596 hasRelatedWork W2493566683 @default.
- W4294549596 hasRelatedWork W2562798986 @default.
- W4294549596 hasRelatedWork W2620908059 @default.
- W4294549596 hasRelatedWork W2621540640 @default.
- W4294549596 hasRelatedWork W3184068009 @default.
- W4294549596 hasVolume "277" @default.
- W4294549596 isParatext "false" @default.
- W4294549596 isRetracted "false" @default.
- W4294549596 workType "article" @default.